PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.56%
Negative R&D growth (spending reduction) needs careful analysis. Benjamin Graham would examine impact on competitive position.
-79.23%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
-99.88%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-74.55%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-74.55%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
-99.95%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
609.47%
D&A growth above 10% signals heavy asset expansion. Seth Klarman would demand evidence of future payoff.
90.56%
EBITDA growth above 15% demonstrates exceptional operating performance. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
74.50%
Operating income growth above 15% demonstrates exceptional core profitability. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
136.63%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
91.74%
Pre-tax income growth above 15% demonstrates exceptional profitability improvement. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
-502.21%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
91.74%
Net income growth above 15% demonstrates exceptional bottom-line expansion. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
91.71%
EPS growth above 15% demonstrates exceptional shareholder value creation. Warren Buffett would verify sustainability.
91.71%
Diluted EPS growth above 15% demonstrates exceptional value creation despite potential dilution. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.